The risk impact of rs36115365-C on PC was calculated by comparing a total of 50 p16-Leiden carriers who developed PC (median age 50) to 143 controls (median age 74) consisting of 62 carriers who did not develop PC and 81 carriers who developed melanoma but were older than 55 years of age (sub-cohort characteristics, Table 2). Here, CDKN2A is linked to pachyonychia congenita.